Date: 2016-09-20
Type of information: Private placement
Company: Agios Pharmaceuticals (USA - MA)
Investors:
Amount: $173 million
Funding type: private placement
Planned used:
Others: * On September 20, 2016, Agios Pharmaceuticals announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 505,617 shares at the public offering price of $44.50 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Agios to 3,876,403 shares and increased the amount of gross proceeds raised in the offering, before underwriting discounts and estimated expenses of the offering, to approximately $173 million . * On September 13, 2016, Agios Pharmaceuticals announced that it is offering to sell, subject to market and other conditions, up to $150 million of its common stock in an underwritten public offering. Agios also intends to grant the underwriters a 30-day option to purchase from it up to an additional $22.5 million of shares. All of the shares in the offering are to be sold by Agios. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
* On September 14, 2016, Agios Pharmaceuticals announced that it has priced an underwritten public offering of 3,370,786 shares of common stock at a price to the public of $44.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $150 million . All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase up to an additional 505,617 shares of common stock on the same terms and conditions. Closing of the offering is expected to occur on or about September 20, 2016 , subject to customary closing conditions.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering.
The shares are being offered by Agios pursuant to an automatically effective shelf registration statement that has been filed with the Securities and Exchange Commission ("SEC").
Therapeutic area: Cancer - Oncology - Rare diseases
